Article ; Online: Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.
2017 Volume 23, Issue 11, Page(s) 1362–1368
Abstract: ... We show that loss of Keap1 hyperactivates NRF2 and promotes KRAS-driven LUAD in mice ... in a mouse model of KRAS-driven LUAD, we examined the effects of Keap1 loss in lung cancer progression ... for stratification of human patients with lung cancer harboring KRAS/KEAP1- or KRAS/NRF2-mutant lung tumors as likely ...
| Abstract | Treating KRAS-mutant lung adenocarcinoma (LUAD) remains a major challenge in cancer treatment given the difficulties associated with directly inhibiting the KRAS oncoprotein. One approach to addressing this challenge is to define mutations that frequently co-occur with those in KRAS, which themselves may lead to therapeutic vulnerabilities in tumors. Approximately 20% of KRAS-mutant LUAD tumors carry loss-of-function mutations in the KEAP1 gene encoding Kelch-like ECH-associated protein 1 (refs. 2, 3, 4), a negative regulator of nuclear factor erythroid 2-like 2 (NFE2L2; hereafter NRF2), which is the master transcriptional regulator of the endogenous antioxidant response. The high frequency of mutations in KEAP1 suggests an important role for the oxidative stress response in lung tumorigenesis. Using a CRISPR-Cas9-based approach in a mouse model of KRAS-driven LUAD, we examined the effects of Keap1 loss in lung cancer progression. We show that loss of Keap1 hyperactivates NRF2 and promotes KRAS-driven LUAD in mice. Through a combination of CRISPR-Cas9-based genetic screening and metabolomic analyses, we show that Keap1- or Nrf2-mutant cancers are dependent on increased glutaminolysis, and this property can be therapeutically exploited through the pharmacological inhibition of glutaminase. Finally, we provide a rationale for stratification of human patients with lung cancer harboring KRAS/KEAP1- or KRAS/NRF2-mutant lung tumors as likely to respond to glutaminase inhibition. |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MeSH term(s) | Adenocarcinoma/genetics ; Adenocarcinoma/metabolism ; Adenocarcinoma/pathology ; Adenocarcinoma of Lung ; Animals ; Clustered Regularly Interspaced Short Palindromic Repeats ; Genes, ras ; Glutaminase/antagonists & inhibitors ; Glutamine/metabolism ; Humans ; Hydrolysis ; Kelch-Like ECH-Associated Protein 1/genetics ; Lung Neoplasms/genetics ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Mice | ||||||||||
| Chemical Substances | KEAP1 protein, human ; Kelch-Like ECH-Associated Protein 1 ; Glutamine (0RH81L854J) ; Glutaminase (EC 3.5.1.2) | ||||||||||
| Language | English | ||||||||||
| Publishing date | 2017-10-02 | ||||||||||
| Publishing country | United States | ||||||||||
| Document type | Journal Article | ||||||||||
| ZDB-ID | 1220066-9 | ||||||||||
| ISSN | 1546-170X ; 1078-8956 | ||||||||||
| ISSN (online) | 1546-170X | ||||||||||
| ISSN | 1078-8956 | ||||||||||
| DOI | 10.1038/nm.4407 | ||||||||||
| Shelf mark |
|
||||||||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 4212: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MG 39: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.